ReviewVaccine2005
A review of vaccine research and development: human acute respiratory infections.
Review in Vaccine, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 85 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
85 citing papers in PubMed, 1 synthesis or guideline pooled it, 198 citations in OpenAlex.
- Global and national influenza-associated hospitalisation rates: Estimates for 40 countries and administrative regions.Journal of global health · 2023Pooled it
- Yogurt supplemented with probiotics can protect the healthy elderly from respiratory infections: A randomized controlled open-label trial.Clinical interventions in aging · 2017Trial
- Virus detection and its association with symptoms during influenza-like illness in a sample of healthy adults enrolled in a randomised controlled vaccine trial.Influenza and other respiratory viruses · 2013Trial
- SARS-CoV-2, Influenza Virus, and Respiratory Syncytial Virus Coinfections Among Symptomatic Outpatients in Lorestan Province, Iran: A Retrospective Cross-Sectional Study.Health science reports · 2026Article
- Dermcidin has antiviral activity and protects against influenza.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Trends in acute respiratory infection and associated factors among under-5 children in Ethiopia.BMC pediatrics · 2026Article
- Repeated introductions and widespread transmission of human metapneumovirus in Côte d'Ivoire.BMC infectious diseases · 2025Article
- Review
- The RNA helicase DHX35 functions as a co-sensor for RIG-I-mediated innate immunity.PLoS pathogens · 2024Article
- Revisiting influenza-hospitalisation estimates from the Burden of Influenza and Respiratory Syncytial Virus Disease (BIRD) project using different extrapolation methods.Journal of global health · 2024Article
- Glycolytic interference blocks influenza A virus propagation by impairing viral polymerase-driven synthesis of genomic vRNA.PLoS pathogens · 2023Article
- MiR-1290: a potential therapeutic target for regenerative medicine or diagnosis and treatment of non-malignant diseases.Clinical and experimental medicine · 2023Review
- Serum 25-Hydroxy Vitamin D Levels in Children with Acute Respiratory Infections Caused by Respiratory Virus or Atypical Pathogen Infection.Nutrients · 2023Article
- Influenza breakthrough infection in vaccinated mice is characterized by non-pathological lung eosinophilia.Frontiers in immunology · 2023Article
- Article
- Influenza and other respiratory viruses in children: prevalence and clinical features.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2022Article
- Respiratory illness virus infections with special emphasis on COVID-19.European journal of medical research · 2022Review
- Understanding the rural-urban disparity in acute respiratory infection symptoms among under-five children in Sub-Saharan Africa: a multivariate decomposition analysis.BMC public health · 2022Article
- Article
- No human respiratory syncytial virus but SARS-CoV-2 found in children under 5 years old referred to Children Medical Center in 2021, Tehran, Iran.Journal of medical virology · 2022Article
25 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Worldwide, acute respiratory infections (ARIs) constitute the leading cause of acute illnesses, being responsible for nearly 4 million deaths every year, mostly in young children and infants in developing countries. The main infectious agents responsible for ARIs include influenza virus, respiratory syncytial virus (RSV), parainfluenza virus type 3 (PIV-3), Streptococcus pneumoniae and Haemophilus influenzae. While effective vaccines against influenza, H. influenzae type b (Hib) and S. pneumoniae infections have been available for several years, no vaccine is available at present against illnesses caused by RSV, PIV-3, metapneumovirus or any of the three novel coronaviruses. In addition, the threat constituted by the multiple outbreaks of avian influenza during the last few years is urgently calling for the development of new influenza vaccines with broader spectrum of efficacy, which could provide immunity against an avian influenza virus pandemic. This article reviews the state of the art in vaccine R&D against ARIs and attempts to address these basic public health questions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.